Incyte Corporation (INCY)
Discovers and sells cancer and blood disorder medicines
$129.93+0.09%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+71.9%
The outlook
INCY is trading near the top of its 52-week range and above both its 50- and 200-day moving averages, reflecting sustained upward momentum. Analyst sentiment leans bullish with a "Buy" consensus, though the average price target sits roughly 11% below the current price. The stock's trailing P/E of 18.4 sits at a moderate valuation relative to its recent strength.
What’s behind the score
Analyst consensusBuy — 2.3 avg of 21 analysts
Price trendAbove its 50- & 200-day averages
52-week range96% of the way from its 52-week low to high
Price targetAvg target -11% vs current price
Analyst price target
~12-month · 21 analysts$115.48average target-11.1% vs now
Now $129.93
Low $71.00High $140.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$25.96B
52-wk high
$132.58
52-wk low
$71.00
50-day avg
$106.82
200-day avg
$100.45
Trailing P/E
18.4